🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s GLUE Holdings & Trades

First Buy
Q1 2026
Duration Held
2 Quarters
Largest Add
Q1 2026
+314,862 Shares
Current Position
363,520 Shares
$8.8 M Value

Ken Fisher's GLUE Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 363,520 shares of Monte Rosa Therapeutics, Inc. (GLUE) worth $8.8 M, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in GLUE, representing a fresh investment thesis on this company. Largest addition occurred in Q2 2026, adding 48,658 shares.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Monte Rosa Therapeutics (GLUE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Monte Rosa Therapeutics (GLUE) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +48,658 Add 15.45% 363,520 $24.20
Q1 2026 +314,862 New Buy 314,862 $16.45

Ken Fisher's Monte Rosa Therapeutics Investment FAQs

Ken Fisher first purchased Monte Rosa Therapeutics, Inc. (GLUE) in Q1 2026, acquiring 314,862 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Monte Rosa Therapeutics, Inc. (GLUE) for 2 quarters since Q1 2026.

Ken Fisher's largest addition to Monte Rosa Therapeutics, Inc. (GLUE) was in Q1 2026, adding 314,862 shares worth $5.18 M.

According to the latest 13F filing for Q2 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 363,520 shares of Monte Rosa Therapeutics, Inc. (GLUE), valued at approximately $8.8 M.

As of the Q2 2026 filing, Monte Rosa Therapeutics, Inc. (GLUE) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Monte Rosa Therapeutics, Inc. (GLUE) was 363,520 shares, as reported at the end of Q2 2026.